⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VNDA News
Vanda Pharmaceuticals Inc.
Form 8-K
sec.gov
VNDA
Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation
prnewswire.com
VNDA
Form 8-K
sec.gov
VNDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
accessnewswire.com
VNDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
accessnewswire.com
VNDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
accessnewswire.com
VNDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
accessnewswire.com
VNDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
prnewswire.com
VNDA
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
prnewswire.com
VNDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
accessnewswire.com
VNDA